Innerbody Labs Testosterone Support Announces Official Website Update Featuring Natural Daily Supplement for Men's Health and Vitality
Updated Product Page Now Highlights Daily Testosterone Support Formula for Adult Men Seeking Natural Energy, Vitality, and Wellness Backed by Research
PALO ALTO, June 09, 2025 (GLOBE NEWSWIRE) --
Innerbody Testosterone Support, a California-based wellness brand developed by Innerbody Research, Inc., has updated its official website to highlight a daily supplement designed to support testosterone health, energy, and physical performance in adult men. Available nationwide, the formula is intended for individuals seeking a natural, consistent addition to their wellness routines.
According to the official product page (https://shop.innerbody.com/products/testosterone-support), Innerbody Testosterone Support works in concert with the body's internal systems to help maintain healthy testosterone levels associated with vitality, stamina, and overall wellness. The product is positioned as a clean, once-daily supplement made for modern lifestyles—no complicated regimens or restrictive dietary requirements.
'We believe that supporting your health should be simple, effective, and transparent,' said a company representative. 'Our testosterone support formula reflects that philosophy and our commitment to natural wellness backed by science.'
Innerbody Research, Inc. confirms that its supplements are manufactured in facilities following rigorous quality assurance protocols. The product is composed of carefully selected ingredients that align with common goals for adult male wellness, such as hormone balance, muscle support, and natural energy maintenance.
As shared on the website, the product includes a satisfaction guarantee for new customers. Additional product details, usage insights, and ordering options are available at the official site.
About Innerbody Testosterone Support
Innerbody Testosterone Support is part of Innerbody Research, Inc., a wellness brand based in Palo Alto, California, focused on delivering research-informed supplements that promote health and longevity. The brand emphasizes transparency, natural formulation, and ease of use to help adults support their wellness goals through daily routines.
Product and Contact Information
Brand: Innerbody Testosterone SupportWebsite: https://shop.innerbody.com/products/testosterone-supportEmail: support@innerbody.comPhone: +1 (650) 456-2677Mailing Address: Innerbody Research, Inc.3790 El Camino Real, Unit 524Palo Alto, CA 94306
Disclaimer
This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement.
CONTACT: Email: support@innerbody.com Phone: +1 (650) 456-2677
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
UnitedHealth Group received multiple bids for Latin American operations
-- UnitedHealth Group (NYSE:UNH) is considering several offers for its Latin American operations, according to a Reuters report on Monday. The move comes as the largest U.S. health insurer faces challenges that include the departure of its CEO and an alleged criminal accounting investigation. The insurer has been attempting to leave Latin America since 2022, with the sale of its Banmedica subsidiary becoming more urgent in recent months due to increasing pressures on multiple fronts, the report said. So far, UnitedHealth has reportedly received four preliminary bids for Banmedica, which operates in Colombia and Chile, with an estimated value of about $1 billion. In May, UnitedHealth's shares dropped 25.5%, and the year-to-date decline stands at 40%. The company withdrew from Brazil in 2023 and from Peru in March 2025. It aims to secure around $1 billion for Banmedica's operations in Colombia and Chile. The company anticipates setting a deadline for final proposals as early as July. The bids reportedly include offers from Washington, D.C.-based private equity firm Acon Investments, Sao Paulo-based private equity firm Patria Investments, Texas non-profit health organization Christus Health, and Lima-based healthcare and insurance provider Auna. The report mentioned that Auna is currently in discussions with a financial partner. Related articles UnitedHealth Group received multiple bids for Latin American operations Tesla shares slip after double downgrade amid Trump feud fallout What are the three big things in markets now? RBC weighs in
Yahoo
34 minutes ago
- Yahoo
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages India's CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information Please contact: Media: Lakshmi Ramakrishna lramakrishna@ Investor & Partnership: Ramkesh Meena bd@
Yahoo
an hour ago
- Yahoo
UMMC expands health care access with UMMC Madison
CANTON, Miss. (WJTV) – The University of Mississippi Medical Center (UMMC) acquired Merit Health Madison, which now operates as UMMC Madison. With 67 licensed beds, officials said the Canton-based hospital will expand UMMC's mission to deliver high-quality, accessible care to more Mississippians while providing additional training opportunities for future health care providers. Lyme-disease isn't the only tick-borne threat. Doctors warn these other diseases are spreading 'As Mississippi's only academic medical center, we must continue to be focused on our three-part mission to educate the next generation of health care providers, conduct impactful research and deliver accessible high-quality health care,' said Dr. LouAnn Woodward, vice chancellor of health affairs. 'Every decision we make is rooted in our mission.' The acquisition was finalized May 1. As the full owner, UMMC will integrate the facility more closely into its academic and health care system. UMMC Madison will continue to provide a wide range of community hospital services, including emergency services, medical-surgical care, ICU, pulmonology, pathology, cardiology, radiology, neurology, nephrology, general surgery and GI services. The hospital will operate as a community hospital. UMMC Madison will also become a training site for medical students, residents and fellows, who will have the opportunity to learn at a community hospital. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
